SLCO1A2 and cholestasis: Furthermore, a high dose of YCHD had the greatest ameliorative effect on cholestasis, increasing the UGT1A1, MRP2, BSEP levels by 2.4-, 2.4-, and 1.6-fold, respectively (Figures 6D,G,I, p < 0.001); OATP1A2 and OATP1A4 levels by 1.6- and 1.3-fold, respectively (Figures 6H,J, p < 0.01); and OCT1and NTCP levels 1.8- and 2.0-fold, respectively (Figures 6A,E, p < 0.05).